The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
Model-based analysis of oligonucleotide arrays: Expression index computation and outlier detection.
Li, C., & Wong, W. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.1.31 · Cited by 3,133
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia
Armstrong, S. A., Staunton, J. E., Silverman, L. B., Pieters, R., den Boer, M. L., Minden, M. D., Sallan, S. E., Lander, E. S., Golub, T. R., & Korsmeyer, S. J. (2002) · Nature Genetics · doi:10.1038/ng765 · Cited by 1,723
Epigenetic therapy of cancer: past, present and future
Yoo, C. B., & Jones, P. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1930 · Cited by 1,289
Li, C., & Hung Wong, W. (2001) · Genome Biology · doi:10.1186/gb-2001-2-8-research0032 · Cited by 976
Suzuki, H., Gabrielson, E., Chen, W., Anbazhagan, R., van Engeland, M., Weijenberg, M. P., Herman, J. G., & Baylin, S. B. (2002) · Nature Genetics · doi:10.1038/ng892 · Cited by 857
Ehrich, M., Nelson, M. R., Stanssens, P., Zabeau, M., Liloglou, T., Xinarianos, G., Cantor, C. R., Field, J. K., & van den Boom, D. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507816102 · Cited by 812
Burnett, A. K., Milligan, D., Prentice, A. G., Goldstone, A. H., McMullin, M. F., Hills, R. K., & Wheatley, K. (2007) · Cancer · doi:10.1002/cncr.22496 · Cited by 619
Silverman, L. R., McKenzie, D. R., Peterson, B. L., Holland, J. F., Backstrom, J. T., Beach, C. L., & Larson, R. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4346 · Cited by 552
Nakamura, T., Largaespada, D. A., Lee, M. P., Johnson, L. A., Ohyashiki, K., Toyama, K., Chen, S. J., Willman, C. L., Chen, I.-M., Feinberg, A. P., et al. (1996) · Nature Genetics · doi:10.1038/ng0296-154 · Cited by 493
Functional Diversity of DNA Methyltransferase Inhibitors in Human Cancer Cell Lines
Stresemann, C., Brueckner, B., Musch, T., Stopper, H., & Lyko, F. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2821 · Cited by 385
Nguyen, C. T., Weisenberger, D. J., Velicescu, M., Gonzales, F. A., Lin, J., Liang, G., & Jones, P. A. (2002) · PubMed · Cited by 383
Preferential response of cancer cells to zebularine
Cheng, J. C., Yoo, C. B., Weisenberger, D. J., Chuang, J., Wozniak, C., Liang, G., Marquez, V. E., Greer, S., Orntoft, T. F., Thykjaer, T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.023 · Cited by 319
Asou, H., Tashiro, S., Hamamoto, K., Otsuji, A., Kita, K., & Kamada, N. (1991) · Blood · doi:10.1182/blood.v77.9.2031.2031 · Cited by 291
Continuous Zebularine Treatment Effectively Sustains Demethylation in Human Bladder Cancer Cells
Cheng, J. C., Weisenberger, D. J., Gonzales, F. A., Liang, G., Xu, G.-L., Hu, Y.-G., Marquez, V. E., & Jones, P. A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.3.1270-1278.2004 · Cited by 222
Liang, G., Gonzales, F. A., Jones, P. A., Orntoft, T. F., & Thykjær, T. (2002) · PubMed · Cited by 205
Epigenetic Therapy of Cancer With 5-Aza-2′-Deoxycytidine (decitabine)
Momparler, R. L. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.07.008 · Cited by 183
Gius, D., Cui, H., Bradbury, C. M., Cook, J., Smart, D. K., Zhao, S., Young, L., Brandenburg, S. A., Hu, Y., Bisht, K. S., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.029 · Cited by 181
Sampath, D., Cortes, J., Estrov, Z., Du, M., Shi, Z., Andreeff, M., Gandhi, V., & Plunkett, W. (2005) · Blood · doi:10.1182/blood-2005-08-3351 · Cited by 160
Epigenetic Modification of CCAAT/Enhancer Binding Protein α Expression in Acute Myeloid Leukemia
Hackanson, B. W., Bennett, K. L., Brena, R. M., Jiang, J., Claus, R., Chen, S., Blagitko-Dorfs, N., Maharry, K., Whitman, S. P., Schmittgen, T. D., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0483 · Cited by 159
Self-citationRaj, K. K., John, A. M., Ho, A. Y. L., Chronis, C., Khan, S. N., Samuel, J., Pomplun, S., Thomas, N. S. B., & Mufti, G. J. (2007) · Leukemia · doi:10.1038/sj.leu.2404796 · Cited by 154
Karpf, A. R., Lasek, A. W., Ririe, T. O., Hanks, A. N., Grossman, D., & Jones, D. A. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.1.18 · Cited by 150
Susceptibility of Nonpromoter CpG Islands to De Novo Methylation in Normal and Neoplastic Cells
Nguyen, C., Liang, G., Nguyen, T. T., Tsao-Wei, D. D., Groshen, S. G., Lübbert, M., Zhou, J., Benedict, W. F., & Jones, P. A. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.19.1465 · Cited by 142
Self-citationKozu, T., Miyoshi, H., Shimizu, K., Maseki, N., Kaneko, Y., Asou, H., Kamada, N., & Ohki, M. (1993) · Blood · doi:10.1182/blood.v82.4.1270.1270 · Cited by 139
Sato, N., Matsubayashi, H., Abe, T., Fukushima, N., & Goggins, M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2471 · Cited by 120
Dlk1 in normal and abnormal hematopoiesis
Sakajiri, S., O’Kelly, J., Yin, D., Miller, C. W., Hofmann, W.-K., Oshimi, K., Shih, L.-Y., Kim, K.-H., Sul, H. S., Jensen, C. H., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2403832 · Cited by 104
Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine
Borthakur, G. M., Ahdab, S. E., Ravandi, F., Faderl, S. H., Ferrajoli, A., Newman, B., Issa, J. J., & Kantarjian, H. M. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190701882146 · Cited by 103
Ben-Kasus, T., Ben‐Zvi, Z., Márquez, V. E., Kelley, J. A., & Agbaria, R. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.04.010 · Cited by 94
Current status of epigenetic treatment in myelodysplastic syndromes
Kuendgen, A., & Lübbert, M. (2008) · Annals of Hematology · doi:10.1007/s00277-008-0477-9 · Cited by 93
Self-citationPINCH-1 Regulates the ERK-Bim Pathway and Contributes to Apoptosis Resistance in Cancer Cells
Chen, K., Tu, Y., Zhang, Y., Blair, H., Zhang, L., & Wu, C. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m707307200 · Cited by 77
Enhancement of antineoplastic action of 5-aza-2???-deoxycytidine by zebularine on L1210 leukemia
Lemaire, M., Momparler, L. F., Bernstein, M. L., Márquez, V. E., & Momparler, R. L. (2005) · Anti-Cancer Drugs · doi:10.1097/00001813-200503000-00009 · Cited by 77
Mechanism-based inhibition of C5-cytosine DNA methyltransferases by 2-H pyrimidinone
Hurd, P. J., Whitmarsh, A. J., Baldwin, G. S., Kelly, S. M., Waltho, J. P., Price, N. C., Connolly, B. A., & HORNBY, D. P. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.2491 · Cited by 72
Scott, S. A., Lakshmikuttyamma, A., Sheridan, D. P., Sanche, S. E., Geyer, C. R., & DeCoteau, J. F. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2006.10.005 · Cited by 72
Rockett, J. C. (2001) · Genome biology · doi:10.1186/gb-2001-2-10-reports0032 · Cited by 65
Lee, T., Karon, M. R., & Momparler, R. L. (1974) · PubMed · Cited by 56
Rüter, B. H., Wijermans, P., Claus, R., Kunzmann, R., & Lübbert, M. (2007) · Blood · doi:10.1182/blood-2007-03-080630 · Cited by 53
Self-citationCell cycle effects and cellular pharmacology of 5-AZA-2?-deoxycytidine
Momparler, R. L., Samson, J., Momparler, L. F., & Rivard, G. (1984) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00269027 · Cited by 51
Nigten, J., Ridder, M. C. B.-D., Erpelinck-Verschueren, C. A. J., Nikoloski, G., van der Reijden, B. A., van Wageningen, S., van Hennik, P. B., de Witte, T., Löwenberg, B., & Jansen, J. H. (2005) · Leukemia · doi:10.1038/sj.leu.2403699 · Cited by 46
Lasa, A., Carnicer, M. J., Aventin, A. M., Estivill, C., Brunet, S., Sierra, J., & Nomdedeu, J. F. (2004) · Leukemia · doi:10.1038/sj.leu.2403377 · Cited by 40
Accordi, B., Pillozzi, S., Dell'Orto, M. C., Cazzaniga, G., Arcangeli, A., Kronnie, G. T., & Basso, G. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m706314200 · Cited by 22
Cited by
Cancer epigenetics reaches mainstream oncology
Rodríguez-Paredes, M., & Esteller, M. (2011) · Nature Medicine · doi:10.1038/nm.2305 · Cited by 1,205
Tsai, H.-C., Li, H., Van Neste, L., Cai, Y., Robert, C., Rassool, F. V., Shin, J. J., Harbom, K. M., Beaty, R., Pappou, E., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.029 · Cited by 650
Lübbert, M., Suciu, S., Baila, L., Rüter, B. H., Platzbecker, U., Giagounidis, A., Selleslag, D., Labar, B., Germing, U., Salih, H. R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.9245 · Cited by 552
Self-citationDNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction
Bröske, A.-M., Vockentanz, L., Kharazi, S., Huska, M. R., Mancini, E., Scheller, M., Kuhl, C., Enns, A., Prinz, M., Jaenisch, R., et al. (2009) · Nature Genetics · doi:10.1038/ng.463 · Cited by 478
A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines
Hollenbach, P. W., Nguyen, A. N., Brady, H., Williams, M., Ning, Y., Richard, N., Krushel, L., Aukerman, S. L., Heise, C., & MacBeth, K. J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009001 · Cited by 362
Metadata
- Authors
- Flotho, C., Claus, R., Batz, C., Schneider, M., Sandrock, I., Ihde, S., Plass, C., Niemeyer, C. M., & Lübbert, M.
- Venue
- Leukemia
- Published
- 2009-02-05
- Volume
- 23
- Issue
- 6
- Pages
- 1019-1028
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W1991858306
- Cited by
- 315
- References
- 40
- FWCI
- 17.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.